EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Unbiased evaluation of rapamycin's specificity as an mTOR inhibitor

Filippo Artoni iD, Nina Grützmacher, Constantinos Demetriades iD

Aging Cell · 2023-08 · 22 (8)

DOI: 10.1111/acel.13888 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Aging Cell, online erschienen am 24.05.2023. Verfasst von Filippo Artoni und 2 weiteren Autor:innen. Beteiligte Einrichtung: Max Planck Institute for Biology of Ageing (MPI-AGE), Cologne, Germany. Hauptthemen laut MEDLINE: MTOR Inhibitors, Signal Transduction. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 107 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: H2020 European Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Rapamycin is a macrolide antibiotic that functions as an immunosuppressive and anti‐cancer agent, and displays robust anti‐ageing effects in multiple organisms including humans. Importantly, rapamycin analogues (rapalogs) are of clinical importance against certain cancer types and neurodevelopmental diseases. Although rapamycin is widely perceived as an allosteric inhibitor of mTOR (mechanistic target of rapamycin), the master regulator of cellular and organismal physiology, its specificity has not been thoroughly evaluated so far. In fact, previous studies in cells and in mice hinted that rapamycin may be also acting independently from mTOR to influence various cellular processes. Here, we generated a gene‐edited cell line that expresses a rapamycin‐resistant mTOR mutant (mTOR RR ) and assessed the effects of rapamycin treatment on the transcriptome and proteome of control or mTOR RR ‐expressing cells. Our data reveal a striking specificity of rapamycin towards mTOR, demonstrated by virtually no changes in mRNA or protein levels in rapamycin‐treated mTOR RR cells, even following prolonged drug treatment. Overall, this study provides the first unbiased and conclusive assessment of rapamycin's specificity, with potential implications for ageing research and human therapeutics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MTOR InhibitorsSignal TransductionMiceHumansAnimalsCell Line, TumorTOR Serine-Threonine KinasesSirolimusMechanistic Target of Rapamycin Complex 1

Stichwörter der Autor:innen

ageingmTORC1proteomicsrapamycinsirolimus

Substanzen

MTOR InhibitorsTOR Serine-Threonine KinasesSirolimusMechanistic Target of Rapamycin Complex 1

Autor:innen und Institutionen

  • Max Planck Institute for Biology of Ageing (MPI-AGE), Cologne, Germany.
  • Cologne Graduate School of Ageing Research (CGA), Cologne, Germany.
  • Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, Cologne, Germany.

ORCID-Profile: Filippo Artoni, Constantinos Demetriades

Förderung

  • H2020 European Research Council

Zitieren

APA

Artoni, F., Grützmacher, N., & Demetriades, C. (2023). Unbiased evaluation of rapamycin's specificity as an mTOR inhibitor. Aging Cell, 22(8). https://doi.org/10.1111/acel.13888

Vancouver

Artoni F, Grützmacher N, Demetriades C. Unbiased evaluation of rapamycin's specificity as an mTOR inhibitor. Aging Cell. 2023;22(8). doi:10.1111/acel.13888

BibTeX
@article{Artoni2023,
  author = {Artoni, Filippo and Grützmacher, Nina and Demetriades, Constantinos},
  title = {Unbiased evaluation of rapamycin's specificity as an mTOR inhibitor},
  journal = {Aging Cell},
  year = {2023},
  volume = {22},
  number = {8},
  doi = {10.1111/acel.13888}
}
Kostenlos starten →